Stivarga(regorafenib)
Regorafenib, Stivarga (regorafenib) is a small molecule pharmaceutical. Regorafenib was first approved as Stivarga on 2012-09-27. It is used to treat colorectal neoplasms, gastrointestinal stromal tumors, and hepatocellular carcinoma in the USA. It has been approved in Europe to treat colorectal neoplasms. The pharmaceutical is active against serine/threonine-protein kinase B-raf. In addition, it is known to target vascular endothelial growth factor receptor 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| digestive system diseases | D004066 |
Trade Name
FDA
EMA
Stivarga (discontinued: Regorafenib)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| stivarga | New Drug Application | 2025-02-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| colorectal neoplasms | — | D015179 | — |
| hepatocellular carcinoma | — | D006528 | C22.0 |
| gastrointestinal stromal tumors | EFO_0000505 | D046152 | C49.A |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
REGORAFENIB, STIVARGA, BAYER HLTHCARE | |||
| 2024-04-27 | ODE-139 | ||
HCPCS
No data
Clinical
Clinical Trials
339 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | 28 | 87 | 20 | 4 | 31 | 151 |
| Neoplasms | D009369 | — | C80 | 26 | 16 | — | 1 | 2 | 39 |
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 6 | 16 | 2 | 1 | 8 | 29 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatocellular carcinoma | D006528 | — | C22.0 | 7 | 27 | 4 | — | 15 | 49 |
| Carcinoma | D002277 | — | C80.0 | 6 | 26 | 4 | — | 10 | 43 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 5 | 26 | 3 | — | 12 | 43 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 6 | 14 | 3 | — | 2 | 23 |
| Adenocarcinoma | D000230 | — | — | 4 | 11 | 1 | — | — | 13 |
| Sarcoma | D012509 | — | — | 2 | 11 | 1 | — | 1 | 12 |
| Colonic neoplasms | D003110 | — | C18 | 3 | 6 | 1 | — | 1 | 11 |
| Glioblastoma | D005909 | EFO_0000515 | — | 2 | 5 | 1 | — | 2 | 8 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | 2 | 4 | 1 | — | 1 | 6 |
| Esophageal neoplasms | D004938 | — | C15 | 2 | 5 | 1 | — | — | 6 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rectal neoplasms | D012004 | — | — | 3 | 7 | — | — | — | 10 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 3 | 7 | — | — | 1 | 9 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 4 | 5 | — | — | 2 | 8 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 6 | — | — | — | 7 |
| Osteosarcoma | D012516 | — | — | 1 | 6 | — | — | 1 | 7 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 3 | 5 | — | — | — | 5 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 5 | — | — | — | 5 |
| Melanoma | D008545 | — | — | 1 | 5 | — | — | — | 5 |
| Cholangiocarcinoma | D018281 | — | C22.1 | — | 5 | — | — | — | 5 |
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | 4 | — | — | — | 4 |
Show 68 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | — | C92.0 | 3 | — | — | — | 1 | 4 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | 1 | 2 |
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | — | — | — | — | 2 |
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | — | — | — | — | 1 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | — | — | — | — | 1 |
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | — | — | — | — | 1 |
Show 11 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | — | — | — | — | 1 | 1 |
| Myeloid leukemia | D007951 | — | C92 | — | — | — | — | 1 | 1 |
| Acute disease | D000208 | — | — | — | — | — | — | 1 | 1 |
| Lymphoid leukemia | D007945 | — | C91 | — | — | — | — | 1 | 1 |
| Disease progression | D018450 | — | — | — | — | — | — | 1 | 1 |
| Progression-free survival | D000077982 | — | — | — | — | — | — | 1 | 1 |
| Leiomyosarcoma | D007890 | — | — | — | — | — | — | 1 | 1 |
| Malignant fibrous histiocytoma | D051677 | — | — | — | — | — | — | 1 | 1 |
| Therapeutic chemoembolization | D016461 | — | — | — | — | — | — | 1 | 1 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Regorafenib |
| INN | regorafenib |
| Description | Regorafenib is a pyridinecarboxamide obtained by condensation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxylic acid with methylamine. Used for for the treatment of metastatic colorectal cancer in patients who have previously received chemotherapy, anti-EGFR or anti-VEGF therapy. It has a role as an antineoplastic agent, a tyrosine kinase inhibitor and a hepatotoxic agent. It is an aromatic ether, a pyridinecarboxamide, a member of monochlorobenzenes, a member of (trifluoromethyl)benzenes, a member of monofluorobenzenes and a member of phenylureas. |
| Classification | Small molecule |
| Drug class | rapidly accelerated fibrosarcoma (RAF) kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1 |
Identifiers
| PDB | — |
| CAS-ID | 755037-03-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1946170 |
| ChEBI ID | 68647 |
| PubChem CID | 11167602 |
| DrugBank | DB08896 |
| UNII ID | 24T2A1DOYB (ChemIDplus, GSRS) |
Target
Agency Approved
BRAF
BRAF
Organism
Homo sapiens
Gene name
BRAF
Gene synonyms
BRAF1, RAFB1
NCBI Gene ID
Protein name
serine/threonine-protein kinase B-raf
Protein synonyms
94 kDa B-raf protein, B-Raf proto-oncogene serine/threonine-protein kinase (p94), B-Raf serine/threonine-protein, murine sarcoma viral (v-raf) oncogene homolog B1, p94, Proto-oncogene B-Raf, v-raf murine sarcoma viral oncogene homolog B, v-Raf murine sarcoma viral oncogene homolog B1
Uniprot ID
Mouse ortholog
Braf (109880)
serine/threonine-protein kinase B-raf (Q3USE9)
Alternate
KDR
KDR
Organism
Homo sapiens
Gene name
KDR
Gene synonyms
FLK1, VEGFR2
NCBI Gene ID
Protein name
vascular endothelial growth factor receptor 2
Protein synonyms
CD309, Fetal liver kinase 1, fetal liver kinase-1, FLK-1, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, tyrosine kinase growth factor receptor
Uniprot ID
Mouse ortholog
Kdr (16542)
vascular endothelial growth factor receptor 2 (Q8VCD0)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 14,031 documents
View more details
Safety
Black-box Warning
Black-box warning for: Stivarga
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10,768 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use